You can buy or sell LQDA and other stocks, options, ETFs, and crypto commission-free!
Liquidia Technologies, Inc. Common Stock, also called Liquidia Technologies, is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. Read More It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded in 2004 and is headquartered in Durham, NC.
Morrisville, North Carolina
52 Week High
52 Week Low
Associated PressMar 18
Liquidia Technologies Announces Proposed Offering of Common Stock
RESEARCH TRIANGLE PARK, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA) (“Liquidia”), a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT® technology to transform the lives of patients, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. All of the shares in the proposed offering will be sold by Liquidia. In addition, Liq...
Seeking AlphaFeb 26
Liquidia Technologies Inc. (LQDA) CEO Neal Fowler on Q4 2018 Results - Earnings Call Transcript
Liquidia Technologies Inc. (NASDAQ:LQDA) Q4 2018 Earnings Conference Call February 26, 2019 8:00 AM ET Company Participants Jenny Kobin - Investor Relations Neal Fowler - Chief Executive Officer Kevin Gordon - President and Chief Financial Officer Dr. Robert Roscigno - SVP of Product Development and Program Lead for LIQ861 Conference Call Participants Liana Moussatos - Wedbush Securities Serge Belanger - Needham & Company Chris Howerton - Jefferies Operator Good day ladies and gentlemen and welco...
Expected May 7, Pre-Market